Mantle cell lymphoma
Mantle cell lymphoma has a poor long-term prognosis which has improved in the last few decades with now quoted median time to treatment failure of just over 9 years. Long term survival is still problematical.
Most are characterised by the t(11;14) translocation that results in a fusion protein between IgH and cyclin D1. Other cyclin D partners have been described.
Chemotherapy is the standard treatment with high-dose cytarabine and immunochemotherapy before autologous stem-cell transplantation being the current standard of treatment in those less than 65 years.
- ↑ Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet (London, England). 2016 Aug 6; 388(10044):565-75.(Link to article – subscription may be required.)